NCT01545141 2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
Clinical Trials
7 trialsNCT02054104 2022-01-26
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02151448 2020-07-20
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
University of Pittsburgh
Phase 1/2 Completed
NCT00970502 2017-04-10
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT01021215 2015-04-02
Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00314262 2014-10-24
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
Emory University
Phase 1/2 Completed
NCT00581971 2013-04-25
RAD0201
University of Alabama at Birmingham
Phase 1/2 Completed